A record of what Rajiv Batra said publicly, with the source. Not advice.
Pending — not yet graded
“Recommends profit-taking in the pharma sector due to concerns over US generics, including potential Section 232 investigations, and underwhelming earnings in the recently concluded quarter. The sector has seen a 40% outperformance over the last three years, making it prudent to reduce exposure given the overhanging risks and high 26x PE valuations.”
Nifty PharmaBearishCalled 22 Aug 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Rajiv Batra’s full track record